Experimental HIV vaccine combo enters first human safety trial
NCT ID NCT06905275
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 31 times
Summary
This early-stage study tests whether two experimental HIV vaccines (UVAX-1107 and UVAX-1197) are safe and can trigger an immune response in healthy adults without HIV. Twenty-five volunteers will receive injections and be monitored for about a year. The goal is to see if the vaccines are well-tolerated and produce antibodies that could protect against HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS (#31788)
Birmingham, Alabama, 35222, United States
-
Columbia P&S CRS (#30329)
New York, New York, 10032, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
Vanderbilt Vaccine (VV) CRS (#30352)
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.